Episode 391: 402. Functional disability after clinically significant extracranial bleeding: a secondary analysis of ASPREE

Episode 391: 402. Functional disability after clinically significant extracranial bleeding: a secondary analysis of ASPREE

https://www.jthjournal.org/article/S1538-7836(25)00109-6/fulltext
Antithrombotic agents, like aspirin and anticoagulants, are essential for treating many cardiovascular conditions. However, a common side effect is bleeding, with extracranial bleeding—bleeding outside the brain and spinal cord—being quite prevalent. This study, a secondary analysis of the Aspirin in Reducing Events in the Elderly, or ASPREE trial, aimed to explore how clinically significant extracranial bleeding affects the development of functional disability in otherwise healthy older adults.

What did the researchers find?

Summary of Findings:

  • Incidence of Bleeding: Out of nearly 19,000 participants, about 2.9%, or 547 individuals, experienced clinically significant extracranial bleeding.
  • Functional Independence Impact: Those who experienced such bleeding had a more than two-fold increase in the risk of developing dependence on activities of daily living, or ADLs. Specifically, the hazard ratio for ADL dependence was 2.46, indicating a significant association.
  • Types of Bleeding: Both gastrointestinal (GI) bleeding and other non-GI extracranial bleeding showed similar risks, with hazard ratios of 2.29 and 2.68 respectively. Importantly, these associations held true whether participants were on aspirin or a placebo.

Strengths of the Study:

  1. Large Sample Size: With nearly 19,000 participants, the study provides robust data.
  2. Rigorous Data Collection: Bleeding events were meticulously documented and adjudicated by medical professionals.
  3. Comprehensive Analysis: The detailed follow-up and frequent assessments allowed for thorough monitoring of participants' health outcomes over several years.

Weaknesses of the Study:

  1. Granular Data Absence: Specific details about hospitalization, such as length of stay or the number of transfusions, were not available.
  2. Data Collection Frequency: Bleeding events were assessed continuously, whereas ADL dependence was assessed biannually. This discrepancy could lead to challenges in pinpointing the exact onset of functional dependence relative to bleeding events.

Jaksot(385)

Episode 302: 301. Development and Validation of the American Heart Association's PREVENT Equations

Episode 302: 301. Development and Validation of the American Heart Association's PREVENT Equations

At change in c stats of 0.007 or 0.0009 is not a meaningful change so I cant say we should use this over the PCE—yes this new calculator has the benefit of removal of race, and the use race-based algo...

12 Kesä 202411min

Episode 301: 300. A New Trial On Beta Blockers and COPD

Episode 301: 300. A New Trial On Beta Blockers and COPD

The problems with observation data is real—  randomized trial, U.K. researchers identified 519 patients (mean age, 68) with mostly moderate COPD (mean forced expiratory volume in 1 second [FEV1], 50%)...

11 Kesä 20246min

Episode 300: 299. When Do You Use a Cluster RCT?

Episode 300: 299. When Do You Use a Cluster RCT?

When you want to do an RCT but you realize there might be some cross contamination so instead of randomizing individuals you randomize cluters or groups Lets say you want to do fluids--- what is bette...

7 Kesä 202414min

Episode 299: 298. Do We Have a Reversal Drug for DOACs? ANNEXA or Andexanet

Episode 299: 298. Do We Have a Reversal Drug for DOACs? ANNEXA or Andexanet

1° outcome: hemostatic efficacy = which was defined as;(A) Hematoma expansion ≤ 35% at 12h(B) increase in NIHSS ≤ 7 at 12h(C) No rescue therapy 3-12h    Results hemostatic efficacy: 76.7% andexanet vs...

6 Kesä 20249min

Episode 298: 297. Which one of the CHADVASC is worse?

Episode 298: 297. Which one of the CHADVASC is worse?

In patients with atrial fibrillation (AF), how do CHA2DS2-VASc 1 subgroups compare with one another    64 141 patients with a first AF diagnosis  Patients were categorized as CHA2DS2-VASc 1 if they ha...

5 Kesä 20244min

Episode 297: FIXED! 296. Is There a Drug That Will Keep Alcoholics Out of the Hospital?

Episode 297: FIXED! 296. Is There a Drug That Will Keep Alcoholics Out of the Hospital?

Bottom line Do I think if you stop drinking alcohol in the next thirty days you are less likely to come to the hospital for a heart attack? A stroke? Pneumonia? copd exacerbations or CHF exacerbations...

30 Touko 202418min

Episode 296: 295. What is the Best Blood Pressure In the Nursing Home?

Episode 296: 295. What is the Best Blood Pressure In the Nursing Home?

In a retrospective cohort study of Veterans Affairs (VA) nursing home residents during 2006 to 2019, researchers identified 13,000 residents who initiated a first or additional antihypertensive medica...

29 Touko 20247min

Episode 295: 294. SGLT2 Inhibitors and Stage 5 CKD

Episode 295: 294. SGLT2 Inhibitors and Stage 5 CKD

SGLT-2 inhibitors have not been evaluated in patients with stage 5 CKD (CKD 5; eGFR, ≤15 mL/minute/1.73 m2). Investigators in Taiwan retrospectively assessed 5 years of outcome data for nearly 48,000 ...

28 Touko 20245min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
psykopodiaa-podcast
tiedenaiset-podcast
voi-hyvin-meditaatiot-2
vakeva-elama-viisaampi-mieli-vahvempi-keho
rss-pitaisko-erota
rss-pt-paahtio
rss-narsisti
puhu-muru
rss-kuumilla-aalloilla
meditaatiot-suomeksi
selviytyjat-tarinoita-elamasta
terapiassa
rss-nautinto
junnut-pelissa
rss-uplevel-by-sonja-hannus
rss-addiktit
rss-mighty-finland-podcast
rss-en-saa-unta
rss-fitissa-podcast